Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trialAlbert M. Maguire, Jean Bennett, Sandro Banfi et al.|The Lancet|2009Cited by 857
Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector AdministrationFrancesca Simonelli, Alberto Auricchio, Albert M. Maguire et al.|Molecular Therapy|2009Cited by 551
AAV2 Gene Therapy Readministration in Three Adults with Congenital BlindnessJean Bennett, Albert M. Maguire, Manzar Ashtari et al.|Science Translational Medicine|2012Cited by 390
SIRT1 activating compounds reduce oxidative stress and prevent cell death in neuronal cellsReas S. Khan, Kenneth S. Shindler|Frontiers in Cellular Neuroscience|2012Cited by 102
Limited sufficiency of antigen presentation by dendritic cells in models of central nervous system autoimmunityGregory F. Wu, Terri M. Laufer, Eric J. Allenspach et al.|Journal of Autoimmunity|2010Cited by 52